Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EQ 
Equillium Inc (EQ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: EQ (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 151.35% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 111.27M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 2 | Beta 1.57 | 52 Weeks Range 0.27 - 2.35 | Updated Date 09/14/2025 |
52 Weeks Range 0.27 - 2.35 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -122% | Operating Margin (TTM) -123.69% |
Management Effectiveness
Return on Assets (TTM) -46.32% | Return on Equity (TTM) -146.92% |
Valuation
Trailing PE - | Forward PE 1.53 | Enterprise Value 100035027 | Price to Sales(TTM) 6.72 |
Enterprise Value 100035027 | Price to Sales(TTM) 6.72 | ||
Enterprise Value to Revenue 6.04 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 59503200 | Shares Floating 42134232 |
Shares Outstanding 59503200 | Shares Floating 42134232 | ||
Percent Insiders 21.55 | Percent Institutions 11.74 |
Upturn AI SWOT
Equillium Inc
Company Overview
History and Background
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders. Founded in 2017 and went public in 2018. Its pipeline targets dysregulated immune responses.
Core Business Areas
- Immunomodulatory Therapeutics: Focuses on developing therapies that modulate the immune system to restore balance in autoimmune and inflammatory diseases.
- Itolizumab (EQ001): Primary drug candidate, a novel anti-CD6 monoclonal antibody, targeting various autoimmune diseases.
Leadership and Structure
Bruce Steel is the CEO. The company has a board of directors and a management team focused on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- Itolizumab (EQ001): Itolizumab is Equillium's lead drug candidate, a first-in-class anti-CD6 monoclonal antibody being developed for multiple severe autoimmune and inflammatory diseases. Equillium is focusing on the treatment of acute Graft-Versus-Host Disease (aGVHD), Lupus nephritis, and uncontrolled Asthma. While itolizumab is approved in India for COVID-19, it is not approved by the FDA for any use in the US. Market share data is currently unavailable. Competitors include companies developing therapies for autoimmune and inflammatory diseases, such as Amgen, Roche, and Johnson & Johnson
Market Dynamics
Industry Overview
The autoimmune and inflammatory disease market is large and growing, with increasing prevalence and unmet medical needs. The market is driven by aging populations, lifestyle changes, and advancements in diagnostics and treatment options.
Positioning
Equillium is positioned as a company developing novel immunomodulatory therapies with a focus on targeting the CD6 pathway. Its competitive advantage lies in its first-in-class anti-CD6 antibody, Itolizumab, and its potential to address underserved patient populations.
Total Addressable Market (TAM)
The total addressable market for autoimmune and inflammatory diseases is estimated to be billions of dollars. Equillium is focusing on specific indications with significant unmet needs, representing a substantial market opportunity. However, Equillium is dependent on the successful testing and FDA approval of their primary product.
Upturn SWOT Analysis
Strengths
- Novel anti-CD6 antibody with a unique mechanism of action
- Focus on underserved patient populations
- Experienced management team
- Potential for multiple indications
Weaknesses
- Limited financial resources
- Reliance on a single product candidate
- Dependent on positive clinical trial results and FDA approval
- Competition from larger pharmaceutical companies
Opportunities
- Expansion into new indications
- Partnerships and collaborations
- Positive clinical trial data leading to regulatory approvals
- Growing market for autoimmune and inflammatory disease therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- AMGN
- RHHBY
- JNJ
Competitive Landscape
Equillium faces intense competition from established pharmaceutical companies. Its success depends on demonstrating the efficacy and safety of Itolizumab and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in terms of clinical development and expanding the potential indications for Itolizumab.
Future Projections: Future growth is dependent on positive clinical trial results, regulatory approvals, and commercialization of Itolizumab.
Recent Initiatives: Recent initiatives include advancing clinical trials in aGVHD, Lupus nephritis, and uncontrolled asthma. Seeking FDA breakthrough therapy designation
Summary
Equillium is a high-risk, high-reward clinical-stage biotech company. Its lead drug candidate, Itolizumab, holds promise for treating severe autoimmune and inflammatory diseases. The company needs to successfully navigate clinical trials and secure regulatory approvals to achieve its growth potential. Financial stability and partnerships will be crucial for its long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Equillium Inc. SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on the most recently available information and may be subject to change. Market share data is estimated and may not be precise. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Equillium Inc
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, President, CEO & Director Mr. Bruce D. Steel C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.equilliumbio.com |
Full time employees 35 | Website https://www.equilliumbio.com | ||
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.